LONG-ACTING INSULIN FORMULATIONSThe application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.Reinhard BeckerAnnke FrickPeter BoderkeChristiane FuerstWerner MuellerKatrin TereschUlrich Werner...
Rapid-acting insulin formulations available in the United States include lispro, aspart, and glulisine, created through amino acid substitutions in the insulin peptide chains. These formulations achieve their desired effect when administered subcutaneously, because intravenous injection leads to a delay in...
Long-acting insulins are used to provide a basal level of insulin. Ultralente insulin reaches a peak gradually (14–18h after injection), with a duration of action of up to 24h. Similar tolenteinsulin, ultralente is a suspension of large, zinc-containing crystals that have been precipitated...
There are a total of 223 marketed long-acting formulations [7]. Figure 1a illustrates the classification of approved LAIs based on the route of administration and 1b therapeutic areas. The current trend shows an increase in chronic disease numbers that require treatment for the long term, includi...
Most pharmaceuticals are given using short-acting formulations that require frequent administration, which can negatively affect patient compliance and increase failure risks associated with inconsistent use. By contrast, long-acting release formulations can achieve sustained release of drugs for weeks, months...
Most pharmaceuticals are given using short-acting formulations that require frequent administration, which can negatively affect patient compliance and increase failure risks associated with inconsistent use. By contrast, long-acting release formulations can achieve sustained release of drugs for weeks, months...
Premixed insulin treatment for type 2 diabetes: analogue or human? The progressive nature of type 2 diabetes makes insulin initiation a necessary therapeutic step for many patients. Premixed insulin formulations containing... AJ Garber,R Ligthelm,JS Christiansen,... - 《Diabetes Obesity & Metabolism...
Glucose-responsive formulations of insulin can increase its therapeutic index and reduce the burden of its administration. However, it has been difficult to develop single-dosage formulations that can release insulin in both a sustained and glucose-responsive manner. Here we report the development of ...
Self-associationoflong-actinginsulinanaloguesstudiedbysizeexclusion chromatographycoupledtomulti-anglelightscattering MaleneH.Jensen a,b,c,∗ ,Per-OlofWahlund c ,JesK.Jacobsen c , BenteVestergaard a,b ,MarcovandeWeert b ,SvendHavelund c,∗∗ a DepartmentofMedicinalChemistry,FacultyofPharmaceuticalSci...
An injectable formulation containing a rapid acting insulin and a long acting insulin has been developed. The pH of the rapid acting insulin is adjusted so that the long acting insu